机译:Minimal residual disease-guided stop and start of venetoclax plus ibrutinib for patients with relapsed or refractory chronic lymphocytic leukaemia (HOVON141/VISION): primary analysis of an open-label, randomised, phase 2 trial
Laboratory of Special Hematology Amsterdam University Medical Center University of Amsterdam;
Department of Hematology Zealand University Hospital;
Department of Hematology Odense University HospitalDepartment of HematologyDepartment of Hematology Rigshospitalet Copenhagen University HospitalDepartment of Hematology Isala ZiekenhuisDepartment of Hematology Turku University Central HospitalDepartment of Hematology Uppsala University HospitalDepartment of Hematology University Medical Center Groningen University of GroningenDepartment of Hematology Akershus University HospitalHOVON Data Center Department of Hematology Erasmus MC Cancer InstituteDepartment of Internal Medicine Albert Schweitzer HospitalDepartment of Hematology Cancer Center Amsterdam Amsterdam University Medical Center University ofDepartment of Hematology Haga HospitalDepartment of Hematology Herlev HospitalDepartment of Hematology St Antonius HospitalDepartment of Hematology University Medical Center UtrechtDepartment of Human Genetics Amsterdam University Medical Center University of Amsterdam;